244 related articles for article (PubMed ID: 28560458)
81. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor.
Wykosky J; Palma E; Gibo DM; Ringler S; Turner CP; Debinski W
Oncogene; 2008 Dec; 27(58):7260-73. PubMed ID: 18794797
[TBL] [Abstract][Full Text] [Related]
82. EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model.
Tandon M; Vemula SV; Sharma A; Ahi YS; Mittal S; Bangari DS; Mittal SK
J Gene Med; 2012 Feb; 14(2):77-89. PubMed ID: 22228563
[TBL] [Abstract][Full Text] [Related]
83. Targeting EPHA2 with Kinase Inhibitors in Colorectal Cancer.
Tröster A; Jores N; Mineev KS; Sreeramulu S; DiPrima M; Tosato G; Schwalbe H
ChemMedChem; 2023 Dec; 18(23):e202300420. PubMed ID: 37736700
[TBL] [Abstract][Full Text] [Related]
84. Activation of erythropoietin-producing hepatocellular receptor A2 attenuates cell adhesion of human fallopian tube epithelial cells via focal adhesion kinase dephosphorylation.
Yang XY; Zhu WJ; Jiang H
Mol Cell Biochem; 2012 Feb; 361(1-2):259-65. PubMed ID: 22009484
[TBL] [Abstract][Full Text] [Related]
85. EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.
Dunne PD; Dasgupta S; Blayney JK; McArt DG; Redmond KL; Weir JA; Bradley CA; Sasazuki T; Shirasawa S; Wang T; Srivastava S; Ong CW; Arthur K; Salto-Tellez M; Wilson RH; Johnston PG; Van Schaeybroeck S
Clin Cancer Res; 2016 Jan; 22(1):230-242. PubMed ID: 26283684
[TBL] [Abstract][Full Text] [Related]
86. Targeting EphA2 in cancer.
Xiao T; Xiao Y; Wang W; Tang YY; Xiao Z; Su M
J Hematol Oncol; 2020 Aug; 13(1):114. PubMed ID: 32811512
[TBL] [Abstract][Full Text] [Related]
87. UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations.
Hassan-Mohamed I; Giorgio C; Incerti M; Russo S; Pala D; Pasquale EB; Zanotti I; Vicini P; Barocelli E; Rivara S; Mor M; Lodola A; Tognolini M
Br J Pharmacol; 2014 Dec; 171(23):5195-208. PubMed ID: 24597515
[TBL] [Abstract][Full Text] [Related]
88. Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor.
Tognolini M; Incerti M; Hassan-Mohamed I; Giorgio C; Russo S; Bruni R; Lelli B; Bracci L; Noberini R; Pasquale EB; Barocelli E; Vicini P; Mor M; Lodola A
ChemMedChem; 2012 Jun; 7(6):1071-83. PubMed ID: 22529030
[TBL] [Abstract][Full Text] [Related]
89. NRAS mutant E132K identified in young-onset sporadic colorectal cancer and the canonical mutants G12D and Q61K affect distinct oncogenic phenotypes.
Yu RTD; Garcia RL
Sci Rep; 2020 Jul; 10(1):11028. PubMed ID: 32620824
[TBL] [Abstract][Full Text] [Related]
90. Systems analysis identifies potential target genes to overcome cetuximab resistance in colorectal cancer cells.
Park SM; Hwang CY; Cho SH; Lee D; Gong JR; Lee S; Nam S; Cho KH
FEBS J; 2019 Apr; 286(7):1305-1318. PubMed ID: 30719834
[TBL] [Abstract][Full Text] [Related]
91. Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling.
Gomez-Soler M; Petersen Gehring M; Lechtenberg BC; Zapata-Mercado E; Hristova K; Pasquale EB
J Biol Chem; 2019 May; 294(22):8791-8805. PubMed ID: 31015204
[TBL] [Abstract][Full Text] [Related]
92. Tobacco smoke induces epithelial barrier dysfunction via receptor EphA2 signaling.
Nasreen N; Khodayari N; Sriram PS; Patel J; Mohammed KA
Am J Physiol Cell Physiol; 2014 Jun; 306(12):C1154-66. PubMed ID: 24717580
[TBL] [Abstract][Full Text] [Related]
93. Analysis of ADAM12-Mediated Ephrin-A1 Cleavage and Its Biological Functions.
Ieguchi K; Tomita T; Takao T; Omori T; Mishima T; Shimizu I; Tognolini M; Lodola A; Tsunoda T; Kobayashi S; Wada S; Maru Y
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33804570
[TBL] [Abstract][Full Text] [Related]
94. An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review.
Fornasier G; Francescon S; Baldo P
Adv Ther; 2018 Oct; 35(10):1497-1509. PubMed ID: 30218345
[TBL] [Abstract][Full Text] [Related]
95. Nanoscale obstacle arrays frustrate transport of EphA2-Ephrin-A1 clusters in cancer cell lines.
Lohmüller T; Xu Q; Groves JT
Nano Lett; 2013 Jul; 13(7):3059-64. PubMed ID: 23668885
[TBL] [Abstract][Full Text] [Related]
96. Protection by the Eph-Ephrin System Against Mesenteric Ischemia-Reperfusion Injury.
Vivo V; Zini I; Cantoni AM; Grandi A; Tognolini M; Castelli R; Ballabeni V; Bertoni S; Barocelli E
Shock; 2017 Dec; 48(6):681-689. PubMed ID: 28472014
[TBL] [Abstract][Full Text] [Related]
97. Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists.
Callegari D; Pala D; Scalvini L; Tognolini M; Incerti M; Rivara S; Mor M; Lodola A
Molecules; 2015 Sep; 20(9):17132-51. PubMed ID: 26393553
[TBL] [Abstract][Full Text] [Related]
98. NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer.
Yang G; Huang L; Jia H; Aikemu B; Zhang S; Shao Y; Hong H; Yesseyeva G; Wang C; Li S; Sun J; Zheng M; Ma J
Oncogene; 2021 Oct; 40(41):5993-6006. PubMed ID: 34385595
[TBL] [Abstract][Full Text] [Related]
99. The SAM domain inhibits EphA2 interactions in the plasma membrane.
Singh DR; Ahmed F; Paul MD; Gedam M; Pasquale EB; Hristova K
Biochim Biophys Acta Mol Cell Res; 2017 Jan; 1864(1):31-38. PubMed ID: 27776928
[TBL] [Abstract][Full Text] [Related]
100. Spatially modulated ephrinA1:EphA2 signaling increases local contractility and global focal adhesion dynamics to promote cell motility.
Chen Z; Oh D; Biswas KH; Yu CH; Zaidel-Bar R; Groves JT
Proc Natl Acad Sci U S A; 2018 Jun; 115(25):E5696-E5705. PubMed ID: 29866846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
